Welcome to our dedicated page for EBR SYS SEC filings (Ticker: EBRCZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EBR Systems, Inc. filings document an emerging growth company’s financial updates, governance votes, and capital-structure changes. The company’s Form 8-K reports include preliminary operating results, commercial and clinical progress, annual and special meeting voting results, and amendments to its certificate of incorporation.
Proxy materials for EBRCZ describe director elections, equity plan matters, shareholder approvals, common stock proposals, CHESS Depositary Interests, and related governance procedures. The filing record also documents the company’s reverse stock split, security issuance ratifications, and recurring disclosure controls around unaudited preliminary financial information.
EBR Systems, Inc. director Will R. Allan reported exercising stock options into common shares. On February 26, 2026, he exercised options covering 58,500 shares at an exercise price of $0.16 per share, receiving the same number of common shares.
Following this transaction, Allan also reports indirect ownership of common stock through related parties, including 5,937,224 shares held by the Allan Will U/A DT 6/14/2012 and 600,000 shares held by family member Taphne Ann Lux. The filing notes these holdings represent common stock underlying Chess Depositary Interests traded on the Australian Securities Exchange.
EBR Systems, Inc. is calling a virtual special meeting of stockholders to approve several corporate actions, led by a reverse stock split of its common stock. The Board is seeking authority to implement a reverse split at any whole-number ratio between 1‑for‑5 and 1‑for‑20, at its discretion, while keeping total authorized common shares at 600,000,000. This would sharply reduce the 450,259,169 shares of common stock currently outstanding and increase the pool of authorized but unissued shares, supporting potential future equity or debt financings. CHESS Depositary Interests (CDIs) will not be consolidated; instead, the CDI‑to‑share ratio will change to match the chosen split ratio, with no expected change in the underlying value per CDI.
Stockholders are also being asked to ratify the prior issuance of 55,900,000 CDIs at A$1.00 each under a 2025 institutional placement that helped raise approximately A$75.9 million to fund commercialization of the WiSE® CRT system, manufacturing scale‑up, sales expansion, R&D, and working capital. Approval would restore capacity under ASX Listing Rule 7.1 for additional future issuances. A third proposal would allow adjournment of the meeting, if needed, to solicit more proxies. The Board unanimously recommends voting “FOR” all three proposals.
EBR Systems, Inc. is asking stockholders at a virtual special meeting to approve a reverse stock split, ratify prior securities issuances, and allow a potential adjournment to gather more votes. The reverse split would combine between 5 and 20 existing shares into 1 new share, with the exact ratio set later by the Board, and would not reduce the 600,000,000 authorized common shares. CHESS Depositary Interests will not be consolidated; instead, the CDI-to-share ratio will change so each CDI continues to reflect the same underlying value after the split.
Because the split reduces shares outstanding without changing authorized shares, the number of authorized but unissued shares would rise, giving the company more flexibility to issue equity in future financings. Stockholders are also asked to ratify the prior issue of 55,900,000 CDIs at A$1.00 each under a 2025 institutional placement so those securities are excluded from the 15% ASX Listing Rule 7.1 limit. As of the record date, 450,259,169 common shares (including CDIs) were outstanding and entitled to vote.
EBR Systems, Inc. filed a current report to share that it has issued a press release describing its commercial and clinical progress and preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company noted that the press release, dated January 12, 2026, includes early estimates only, which are unaudited and may change once normal closing and audit procedures are completed.
The press release, titled “EBR Announces Strong Q4 FY 2025 Commercial and Clinical Progress,” is furnished as an exhibit and is not deemed filed for liability purposes under securities laws, nor automatically incorporated into other securities filings unless specifically referenced.
EBR Systems, Inc. reported Q3 2025 results as it begins commercial rollout of its WiSE CRT System following FDA approval on April 11, 2025. Revenue reached $512,093, generating gross profit of $223,722. Operating expenses were $12.1 million (R&D $6.24 million; SG&A $5.86 million), resulting in an operating loss of $11.88 million and a net loss of $12.19 million for the quarter. For the nine months, revenue was $681,797 with a net loss of $34.71 million.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $70.40 million, including cash and equivalents of $12.64 million and short-term marketable securities of $55.72 million. Notes payable, net, were $40.73 million with maturity in 2027. Inventory increased to $11.17 million as production scaled. Stockholders’ equity was $38.65 million. Shares outstanding were 449,889,450 as of September 30, 2025; the company reported 449,994,658 outstanding as of November 12, 2025.